A CRO's Project Manager is Often the Key to Successful Business Procurement
Applied Clinical Trials
ISR's research consistently finds that a CRO's Project Manager often makes the difference between winning and losing a project for the service provider. Not only the number of years experience, or the number of similar projects managed, but also the communication skills and style demonstrated throughout the bidding process.
ISR's research consistently finds that a CRO's Project Manager often makes the difference between winning and losing a project for the service provider. Not only the number of years experience, or the number of similar projects managed, but also the communication skills and style demonstrated throughout the bidding process.
Sponsors Rate Project Manager Quality
In a recent study of the central labs market (See: The State of the Central Labs Market; www.isrreports.com) the impact that a Project Manager has on sponsors' experiences throughout the delivery of a project was examined. This chart illustrates the high degree to which central lab project management is correlated with overall delivery quality (although the brands are obscured in this article). Service providers with highly rated PMs also tend to receive higher overall quality ratings.
If you are a service provider and want to differentiate your offering based on quality, then hire and train the best Project Managers you can find. If you are a sponsor and you want the highest quality central lab experience, then make sure you get the service provider's best Project Managers.
—Industry Standard Research, www.isrreports.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
